Cryopreservation is not a new technology, but there is still much to explore and perfect in the field. Current methods use slow freezing, a method that is conducive to ice formation, cell dehydration and an increase in cryoprotective agents (CPAs). These are not ideal circumstances for achieving immaculately cryopreserved cells. Researchers from the University of Tokyo use vitrification, a process that transforms a substance into a noncrystalline solid by rapid cooling. This cooling yields favorable outcomes in biological samples, even those that are typically difficult to freeze and thaw successfully. Despite challenges within this method, the future of regenerative medicine research may be greatly, and positively, impacted by the use of vitrification for cell cryopreservation.

A large population-based study has found that older adults with atrial fibrillation who also have metabolic dysfunction-associated steatotic liver disease face a significantly higher risk of developing heart failure. The risk becomes even greater when metabolic liver disease is combined with alcohol exposure. The findings highlight the emerging “liver–heart axis” and suggest that liver health may be an overlooked factor in cardiovascular risk assessment.

Researchers have uncovered a key cellular communication network that drives resistance to gemcitabine in pancreatic cancer. By integrating bulk, single-cell and spatial transcriptomics with experimental validation, the study identifies crosstalk between PRRX2-positive epithelial cells and SPP1-positive macrophages as a central mechanism promoting tumor aggressiveness and poor prognosis. The findings highlight new biomarkers and suggest potential combination treatment strategies to overcome chemotherapy resistance.

HIV exhausts the body’s immune system by overactivating it, despite effective antiviral treatment. Researchers from Linköping University in Sweden have conducted cell studies showing that an existing medication restores immune cell function. The findings, published in the journal PLOS pathogens, raise hopes that this medication could improve the health of people living with HIV.